Ipsen S.A. ADR (IPSEY) CEO David Meek on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha]
IPSEN SA S/ADR (IPSEY)
NASDAQ:AMEX Investor Relations:
ipsen.com/investors
Company Research
Source: Seeking Alpha
Ipsen S.A. ADR (IPSEY) CEO David Meek on Q2 2019 Results - Earnings Call Transcript Ipsen S.A. ADR ( OTCPK:IPSEY Company Participants David Meek - CEO Aymeric Chatelier - EVP and CFO Conference Call Participants Emily Field - Barclays Thibault Boutherin - Morgan Stanley Luisa Hector - Exane BNP Paribas Sachin Jain - Bank of America Merrill Lynch Matt Weston - Credit Suisse Sarita Kapila - JPMorgan Andrew Frost - UBS Delphine Le Louet - Societe Generale Operator Good afternoon, ladies and gentlemen and thank you all for standing by. Welcome to today's Ipsen H1 2019 Results. At this time, all participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session. [Operator Instructions] I must advise also that this call is being recorded today, Thursday, the 25th of July, 2019. And without any further delay, I would now like to hand over the call to your speaker today, David Meek. Thank you. Please go ahead. Good morning and good afternoon. Welcom
Show less
Read more
Impact Snapshot
Event Time:
IPSEY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSEY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSEY alerts
High impacting IPSEN SA S/ADR news events
Weekly update
A roundup of the hottest topics
IPSEY
News
- Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGSGlobeNewswire
- Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritusGlobeNewswire
- Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidanceGlobeNewswire
- Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver diseaseGlobeNewswire
- Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decadeGlobeNewswire